Genus Capital Management Inc. Trims Stake in Boston Scientific Corporation $BSX

Genus Capital Management Inc. trimmed its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 88.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,325 shares of the medical equipment provider’s stock after selling 25,722 shares during the quarter. Genus Capital Management Inc.’s holdings in Boston Scientific were worth $317,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in Boston Scientific by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock worth $13,319,060,000 after buying an additional 1,436,550 shares in the last quarter. Invesco Ltd. grew its position in Boston Scientific by 0.7% during the third quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider’s stock worth $1,656,131,000 after buying an additional 111,826 shares in the last quarter. Northern Trust Corp grew its position in Boston Scientific by 0.9% during the third quarter. Northern Trust Corp now owns 14,402,636 shares of the medical equipment provider’s stock worth $1,406,129,000 after buying an additional 128,188 shares in the last quarter. Amundi grew its position in Boston Scientific by 17.5% during the third quarter. Amundi now owns 11,981,584 shares of the medical equipment provider’s stock worth $1,158,619,000 after buying an additional 1,781,830 shares in the last quarter. Finally, Legal & General Group Plc grew its position in Boston Scientific by 4.6% during the third quarter. Legal & General Group Plc now owns 10,457,175 shares of the medical equipment provider’s stock worth $1,020,934,000 after buying an additional 463,889 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on BSX shares. BTIG Research reiterated a “buy” rating and issued a $80.00 price objective on shares of Boston Scientific in a report on Monday, May 18th. Weiss Ratings cut Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Robert W. Baird cut their price objective on Boston Scientific from $78.00 to $75.00 and set an “outperform” rating for the company in a report on Tuesday, May 19th. Evercore cut their price objective on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. Finally, Argus upgraded Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $92.71.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig bought 3,580 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the acquisition, the director directly owned 25,359 shares of the company’s stock, valued at $1,437,348.12. The trade was a 16.44% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David C. Habiger bought 2,250 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the acquisition, the director directly owned 13,878 shares in the company, valued at $776,057.76. This trade represents a 19.35% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased 9,800 shares of company stock worth $554,012 in the last ninety days. 0.34% of the stock is owned by company insiders.

Boston Scientific Price Performance

BSX opened at $57.71 on Tuesday. The stock has a market capitalization of $85.77 billion, a P/E ratio of 24.15, a PEG ratio of 1.06 and a beta of 0.62. Boston Scientific Corporation has a 12-month low of $52.52 and a 12-month high of $109.50. The stock has a 50-day moving average price of $61.75 and a 200-day moving average price of $79.83. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.Boston Scientific’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts predict that Boston Scientific Corporation will post 3.38 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has authorized a stock repurchase plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.